Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial
Open Access
- 1 April 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 257 (8), 1330-1337
- https://doi.org/10.1007/s00415-010-5526-3
Abstract
Lower limb spasticity in post-stroke patients can impair ambulation and reduces activities of daily living (ADL) performance of patients. Botulinum toxin type A (BoNTA) has been shown effective for upper limb spasticity. This study assesses the treatment of lower limb spasticity in a large placebo-controlled clinical trial. In this multicenter, randomized, double-blind, parallel-group, placebo-controlled study, we evaluate the efficacy and safety of one-time injections of botulinum toxin type A (BoNTA) in Japanese patients with post-stroke lower limb spasticity. One hundred twenty patients with lower limb spasticity were randomized to a single treatment with BoNTA 300 U or placebo. The tone of the ankle flexor was assessed at baseline and through 12 weeks using the Modified Ashworth Scale (MAS). Gait pattern and speed of gait were also assessed. The primary endpoint was area under the curve (AUC) of the change from baseline in the MAS ankle score. Significant improvement in spasticity with BoNTA 300 U was demonstrated by a mean difference in the AUC of the change from baseline in the MAS ankle score between the BoNTA and placebo groups (−3.428; 95% CIs, −5.841 to −1.016; p = 0.006; t test). A significantly greater decrease from baseline in the MAS ankle score was noted at weeks 4, 6 and 8 in the BoNTA group compared to the placebo group (p < 0.001). Significant improvement in the Clinicians Global Impression was noted by the investigator at weeks 4, 6 and 8 (p = 0.016–0.048, Wilcoxon test), but not by the patient or physical/occupational therapist. Assessments of gait pattern using the Physician’s Rating Scale and speed of gait revealed no significant treatment differences but showed a tendency towards improvement with BoNTA. No marked difference was noted in the frequency of treatment-related adverse events between BoNTA and placebo groups. This was the first large-scale trial to indicate that BoNTA significantly reduced spasticity in lower limb muscles.Keywords
This publication has 25 references indexed in Scilit:
- Botulinum Toxin A—When is a Unit Not a Unit?Journal of Urology, 2009
- Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled studyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Comparing two botulinum toxin type A formulations using manufacturers? product summariesJournal of Clinical Pharmacy & Therapeutics, 2007
- Comparison of Botulinum Neurotoxin Preparations for the Treatment of Cervical DystoniaClinical Therapeutics, 2007
- Pooled Analysis of the Safety of Botulinum Toxin Type A in the Treatment of Poststroke SpasticityArchives Of Physical Medicine and Rehabilitation, 2006
- A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic footNeurological Sciences, 2005
- Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsyEuropean Journal of Neurology, 1999
- A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Botulinum toxin A for spasticity, muscle spasms, and rigidityNeurology, 1995
- Analysis of serial measurements in medical research.BMJ, 1990